Table 3.
Anal cytology and histology results at baseline, month 6 and month 12 visits.
|
Anal
cytology |
Anal histology
|
|||||||
|---|---|---|---|---|---|---|---|---|
| Normal HRA, No Biopsy |
Abnormal HRA, Refused Biopsy |
Normal | AIN 1 | AIN 2 | AIN 3 | Inadequate | Total | |
| Baseline | ||||||||
| Normal | 104 | 1 | 21 | 55 | 13 | 13 | 0 | 207 |
| ASC-US | 1 | 0 | 0 | 12 | 1 | 4 | 0 | 18 |
| LSIL | 0 | 0 | 0 | 8 | 0 | 1 | 0 | 9 |
| HSIL | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 3 |
| Missing/ Inadequate |
5 | 0 | 1 | 1 | 1 | 1 | 0 | 9 |
| Total |
110
(45%) |
1
(0.4%) |
22
(9%) |
79
(32%) |
15
(6%) |
19
(8%) |
0 |
246
(100%) |
| Month 6 | ||||||||
| Normal | 29 | 1 | 7 | 19 | 4 | 8 | 1 | 69 |
| ASC-US | 1 | 0 | 1 | 8 | 2 | 0 | 1 | 13 |
| LSIL | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 3 |
| HSIL | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 2 |
| Missing/ Inadequate |
1 | 0 | 0 | 1 | 1 | 2 | 0 | 5 |
| Total |
31
(34%) |
1
(1%) |
9
(10%) |
32
(35%) |
7
(8%) |
10
(11%) |
2
(2%) |
92
(100%) |
| Month 12 | ||||||||
| Normal | 64 | 2 | 15 | 20 | 2 | 5 | 0 | 108 |
| ASC-US | 7 | 2 | 1 | 13 | 5 | 6 | 0 | 34 |
| LSIL | 0 | 1 | 0 | 9 | 1 | 3 | 1 | 15 |
| HSIL | 0 | 1 | 0 | 2 | 1 | 0 | 0 | 4 |
| Missing/ Inadequate |
2 | 0 | 2 | 2 | 0 | 0 | 0 | 6 |
| Total |
73
(44%) |
6
(4%) |
18
(11%) |
46
(28%) |
9
(5%) |
14
(8%) |
1
(0.5%) |
167
(100%) |
AIN, anal intraepithelial neoplasia; ASC-US, atypical squamous cells of undetermined significance; LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesion.
Percentages are rounded and may not always add up to 100%.